Tag

Disease Progression

All articles tagged with #disease progression

health1 month ago•5 min saved

Air Pollution May Raise ALS Risk and Accelerate Its Progression

A JAMA Neurology study (via The Conversation) ties long-term exposure to outdoor air pollution—especially traffic-related PM10 and nitrogen dioxide—to a 20–30% higher risk of developing amyotrophic lateral sclerosis and to faster disease progression in diagnosed patients, notably in motor and respiratory function. The analysis used up-to-10-year air-pollution data at participants’ home addresses and included sibling comparisons to reduce confounding. Limitations include missing data on smoking and indoor pollution. If corroborated, these findings underscore the broader health impact of polluted air and potential avenues for earlier ALS diagnosis and management.

via ScienceAlert|

#air-pollution #als #disease-progression

health1 month ago•4 min saved

Common Diabetes Treatment May Exacerbate the Disease, Study Finds

A new study warns that long-term use of sulphonylureas, common diabetes drugs, may impair insulin-producing beta cells by causing them to lose their functional identity, potentially accelerating the progression of type 2 diabetes. The research suggests that these drugs could contribute to the decline in treatment efficacy over time, but also highlights that loss of cell identity might be reversible, opening avenues for future therapies.

via SciTechDaily|

#beta-cells #diabetes #disease-progression

health5 months ago•11 min saved

Advances in Alzheimer’s and Dementia Treatments: Hope, Challenges, and Innovations

New anti-amyloid drugs for Alzheimer's show promise in slowing disease progression but come with significant risks like brain bleeds and high costs, leading to cautious optimism among neurologists about their use and effectiveness.

via Nature|

#alzheimers-drugs #anti-amyloid-therapy #brain-side-effects

health1 year ago•3 min saved

Long-term Tysabri use shows sustained disease inactivity in patients

A study from Hungary found that a majority of relapsing-remitting multiple sclerosis (RRMS) patients treated with Tysabri (natalizumab) experienced no evidence of disease activity (NEDA-3) for up to six years. The study, involving 121 patients, showed that 80.2% reached NEDA-3, with the highest rate in the first year. Tysabri stabilized dexterity, walking function, and improved cognition, while maintaining quality of life. Patients with lower disability scores were more likely to achieve NEDA-3, and those previously on injectable therapies were less likely to reach this outcome.

via Multiple Sclerosis News Today|

#cognitive-function #disease-progression #health

health1 year ago•2 min saved

Gut Microbiome's Role in Rheumatoid Arthritis Uncovered

Research led by the University of Leeds has identified specific changes in the gut microbiome of individuals at risk of rheumatoid arthritis (RA), potentially uncovering mechanisms of disease onset. The study found significant differences in the abundance of Prevotellaceae in individuals who progressed to RA, with gut microbiome instability observed around ten months before clinical arthritis onset. These findings suggest that understanding microbiome dynamics could enhance RA prediction, prevention, and personalized treatment strategies.

via Medical Xpress|

#autoimmune-disorders #disease-progression #gut-microbiome

health-neuroscience1 year ago•5 min saved

"Predicting Parkinson's Progression with Eye Tests"

Optical coherence tomography, commonly used in eye exams, can monitor neurodegeneration in Parkinson’s disease patients by measuring the thickness of the retina, which often precedes cognitive and motor decline. This method offers a potential early indicator of disease progression, suggesting that routine eye exams could become a non-invasive tool for predicting the future severity of Parkinson’s symptoms and aiding in more targeted treatment strategies.

via Neuroscience News|

#disease-progression #health-neuroscience #neurodegenerative-diseases

health1 year ago•2 min saved

"GLP-1 Drug Shows Promise in Slowing Parkinson's Progression, Study Finds"

Researchers have found that a type 2 diabetes medication called lixisenatide may slow the progression of symptoms in Parkinson's disease, supporting the theory that Parkinson's could be associated with insulin resistance in the brain. In a study, participants given lixisenatide showed essentially no progression of motor problems, while those given a placebo showed worsening symptoms. However, some participants receiving lixisenatide reported nausea and vomiting. The findings pave the way for larger phase 3 clinical trials and suggest that GLP-1R agonists have potential for treating Parkinson's.

via The Guardian|

#diabetes-medication #disease-progression #health

health-and-medicine2 years ago•4 min saved

"Advanced Methods for Accurate Alzheimer's Progression Prediction"

Researchers at The University of Texas at Arlington have developed a new learning-based framework called DETree to accurately predict the progression of Alzheimer’s disease, surpassing the accuracy of existing prediction models. This tool can predict five clinical groups of Alzheimer’s disease development with high accuracy, providing valuable insights for patients and caregivers to plan future care. The framework has the potential to be applied to other diseases with multiple developmental stages, such as Parkinson’s and Huntington’s disease.

via Neuroscience News|

#alzheimers-disease #caregiving #disease-progression

health2 years ago•4 min saved

"Predicting MS Progression: Spinal Cord Atrophy and Chronic Inflammation"

A new study highlights the association of spinal cord atrophy and brain paramagnetic rim lesions with progression independent of relapse activity (PIRA) in people with multiple sclerosis (MS). The research suggests that PIRA, or "silent progression," is accompanied by greater spinal cord atrophy and a higher number of lesions with chronic inflammation. These findings emphasize the need for early recognition of PIRA in clinical practice to prevent irreversible tissue loss and may lead to the development of targeted treatments for patients with PIRA.

via Multiple Sclerosis News Today|

#chronic-inflammation #disease-progression #health

medical2 years ago•3 min saved

"Relyvrio's CENTAUR Data Shows Promising Reduction in ALS Inflammatory Biomarkers"

Treatment with Relyvrio, an oral therapy developed by Amylyx Pharmaceuticals, significantly reduced blood levels of neuroinflammatory biomarkers in people with amyotrophic lateral sclerosis (ALS) as early as three months, according to a post hoc analysis of the CENTAUR trial. The reductions in biomarkers, C-reactive protein (CRP) and YKL-40, were correlated with slowing disease progression. Relyvrio also met its primary goal of slowing functional decline and extended median survival in ALS patients. Further analysis of neuroinflammatory biomarkers is planned in the ongoing Phase 3 PHOENIX trial.

via ALS News Today|

#als #centaur-trial #disease-progression

medical-research2 years ago•4 min saved

Uncovering Factors Influencing ALS Progression: Groundbreaking Study in 2023

A recent analysis of data from the PRECISION-ALS project has identified genetic and clinical factors that can influence the progression of amyotrophic lateral sclerosis (ALS). Factors such as C9ORF72 genetic mutations, bulbar-onset disease, and faster functional declines were associated with shorter survival times. Variations were observed among different centers in the timing of interventions like feeding tube placement and noninvasive ventilation, highlighting the need for further investigation. The PRECISION-ALS project aims to better understand the natural history of ALS and improve outcomes for patients.

via ALS News Today|

#als #clinical-factors #disease-progression

health2 years ago•3 min saved

"Promising Enzyme Inhibitor Halts Parkinson's Progression in Mice"

Inhibiting the enzyme USP30 in a mouse model has been found to protect dopamine-producing neurons, which are typically lost as Parkinson's disease progresses. This groundbreaking discovery offers a new therapeutic approach that could potentially slow or even prevent the progression of Parkinson's. The study utilized genetic knockout models and a proprietary molecule to block USP30, resulting in increased clearance of damaged mitochondria. These findings provide hope for the development of treatments that could modify the course of Parkinson's disease.

via Neuroscience News|

#disease-progression #dopamine-producing-neurons #enzyme-inhibition

health2 years ago•4 min saved

Breakthrough: Scientists Successfully Stop Parkinson's Disease in Mice

Researchers at Beth Israel Deaconess Medical Center have made significant progress in understanding the progression of Parkinson's disease (PD) by inhibiting a specific enzyme in a mouse model. By targeting the enzyme USP30, which plays a role in the clearance of dysfunctional mitochondria in dopamine-producing neurons, the researchers were able to protect against the loss of these neurons and halt the development of PD-like motor symptoms. These findings offer potential for the development of therapeutics that could slow or prevent the progression of Parkinson's disease in humans.

via Medical Xpress|

#disease-progression #dopamine-producing-neurons #enzyme-inhibition

health2 years ago•4 min saved

Unraveling the Mysteries of Multiple Sclerosis: Immune Cells, Fat Metabolism, and Biomarkers

Changes in immune cell activity, immune signaling molecules, iron regulation, and fat metabolism may explain why multiple sclerosis (MS) progresses differently in individuals. Researchers compared gene expression profiles in secondary progressive MS (SPMS) and benign MS, finding over 200 genes expressed at significantly altered levels in SPMS. SPMS patients showed increased activity in genes associated with B-cells and natural killer cells, as well as differences in cytokines, antigen presentation, lipid metabolism, and iron regulation. These findings provide insights into the molecular mechanisms underlying MS progression and may lead to the identification of new targets for preventing or slowing disease progression.

via Multiple Sclerosis News Today|

#disease-progression #gene-expression #health

health2 years ago•3 min saved

Exercise and Tai Chi: Effective Ways to Slow Parkinson's Disease Progression

Researchers at Sacramento State are conducting a study to determine if exercise can slow the progression of Parkinson's disease. Led by Dr. Gwénaëlle Begue and Dr. Matt J.N. Brown, the study involves more than 20 participants who exercise both at home and in person at the Human Performance Research Laboratory. The goal is to find a level of exercise that can potentially slow or stop the symptoms of Parkinson's disease, offering hope for patients like Tony Cepeda, who experiences reduced symptoms when he works out.

via KCRA Sacramento|

#disease-progression #exercise #health